Suppression of Puerperal Lactation with an Ergot Alkaloid: A Double-blind Study
Authors:
- L. VargaLVL. Varga
- P. M. LutterbeckPLP. M. Lutterbeck
- J. S. PryorJPJ. S. Pryor
- R. WennerRWR. Wenner
- H. ErbHEH. Erb
Abstract
A double-blind trial was performed in 60 women to establish the effectiveness of an ergot alkaloid, 2-Br-alpha-ergocryptine (ergocryptine; CB 154), in suppressing puerperal lactation and to compare it with stilboestrol and a placebo. At the doses selected ergocryptine and stilboestrol were equally effective.Keywords
This publication has 22 references indexed in Scilit:
- Treatment of Non-puerperal Galactorrhoea with an Ergot AlkaloidBMJ, 1971
- Plasma Prolactin Activity in Inappropriate LactationBMJ, 1971
- Growth inhibition of rat mammary carcinoma and endocrine changes produced by 2-Br-α-ergocryptine, a suppressor of lactation and nidationEuropean Journal of Cancer (1965), 1970
- Effects of ergocornine and 2-Br-α-ergokryptin (CB-154) on the formation of mammary hyperplastic alveolar nodules and the pituitary prolactin levels in miceCellular and Molecular Life Sciences, 1970
- Oestrogens and puerperal thrombosis.BMJ, 1968
- Inhibition of lactation with combined oestrogen and progestogen.BMJ, 1968
- Puerperal thromboembolism.BMJ, 1968
- Puerperal Thromboembolism in Relation to the Inhibition of Lactation by Oestrogen TherapyBMJ, 1968
- Increased factor IX levels in puerperium during administration of diethylstilboestrol.BMJ, 1968
- PUERPERAL THROMBOEMBOLISM AND SUPPRESSION OF LACTATIONThe Lancet, 1967